KNSA (STOCKS)
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
$44.710000
-0.270000 (-0.60%)
Prev close: $44.980000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Sanj K. Patel
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,390.50M
- Employees
- 315
- P/E (TTM)
- 100.31
- P/B (TTM)
- 6.34
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$0.23 | $0.33 | -0.0998 | -30.26% |
|
Jun 2025 (Q2)
|
$0.23 | $0.19 | +0.0442 | +23.79% |
|
Mar 2025 (Q1)
|
$0.11 | $0.04 | +0.0672 | +157.01% |
|
Dec 2024 (Q4)
|
$-0.12 | $0.00 | -0.1180 | -5,900.00% |
Financial Statements
| Revenues | $597.97M |
| Benefits Costs and Expenses | $549.35M |
| Cost Of Revenue | $74.62M |
| Costs And Expenses | $549.35M |
| Gross Profit | $523.35M |
| Operating Expenses | $485.20M |
| Selling, General, and Administrative Expenses | $180.03M |
| Depreciation and Amortization | $1.49M |
| Research and Development | $97.46M |
| Other Operating Expenses | $206.60M |
| Operating Income/Loss | $38.15M |
| Income/Loss From Continuing Operations After Tax | $35.92M |
| Income/Loss From Continuing Operations Before Tax | $48.62M |
| Income Tax Expense/Benefit | $12.70M |
| Income Tax Expense/Benefit, Deferred | $6.70M |
| Net Income/Loss | $35.92M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $35.92M |
| Net Income/Loss Available To Common Stockholders, Basic | $35.92M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.49 |
| Diluted Earnings Per Share | $0.45 |
| Basic Average Shares | 148,057,267 |
| Diluted Average Shares | 157,320,294 |
| Assets | $712.33M |
| Current Assets | $475.53M |
| Cash | $352.10M |
| Inventory | $41.40M |
| Other Current Assets | $82.03M |
| Noncurrent Assets | $236.80M |
| Fixed Assets | $1.66M |
| Other Non-current Assets | $235.15M |
| Liabilities | $176.95M |
| Current Liabilities | $123.59M |
| Accounts Payable | $6.15M |
| Wages | $17.04M |
| Other Current Liabilities | $100.41M |
| Noncurrent Liabilities | $53.36M |
| Equity | $535.38M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $535.38M |
| Liabilities And Equity | $712.33M |
| Net Cash Flow From Operating Activities | $102.86M |
| Net Cash Flow From Operating Activities, Continuing | $102.86M |
| Net Cash Flow From Investing Activities | -$52.89M |
| Net Cash Flow From Investing Activities, Continuing | -$52.89M |
| Net Cash Flow From Financing Activities | $27.51M |
| Net Cash Flow From Financing Activities, Continuing | $27.51M |
| Net Cash Flow | $77.48M |
| Net Cash Flow, Continuing | $77.48M |
| Comprehensive Income/Loss | $35.69M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $35.80M |
| Other Comprehensive Income/Loss | $18.21M |
| Other Comprehensive Income/Loss Attributable To Parent | -$114.00K |